Evidence map›Paper›PMID 39958926›Full record

ReviewLiver research (Beijing, China)2021

B cell dysfunction in chronic hepatitis B virus infection.

Lijie Ma, Xuehua Sun, Xiaoni Kong, Yueqiu Gao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Liver research (Beijing, China), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lijie MaInstitute of Clinical Immunology, Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xuehua SunInstitute of Clinical Immunology, Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaoni KongInstitute of Clinical Immunology, Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yueqiu GaoInstitute of Clinical Immunology, Department of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B (CHB) remains a global health problem. The persistence of hepatitis B surface antigen (HBsAg) in the blood for longer than 6 months after the initial infection is a sign of CHB. The therapeutic goal for the functional cure of CHB is the generation of antibodies against HBsAg. However, the adaptive immune response of patients with CHB cannot generate an efficient antiviral response. Many previous studies have evaluated T cell function and T cell therapy specifically designed to counter hepatitis B virus (HBV) infection. As one of the major components of adaptive immunity, B cells also display dysfunctions in anti-HBsAg antibody (HBsAb) production and antigen presentation. Patients with CHB have amplification of CD19

Indexed as

Antigen-presenting cells (APCs)Atypical memory B cells (atMBCs)B cell dysfunctionChronic hepatitis B virus infectionHepatitis B surface antibodyRegulatory B cells (Bregs)

Identifiers

PMID39958926
PMCPMC11791862

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.